Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Chemotherapy. Immunotherapy. Fox Chase Cancer Center, Philadelphia, PA, United States



Survival: 60.8 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
Immunotherapy
   
Drugs:
Country: United States
   
City/State/Province: Philadelphia, PA
   
Hospital: Fox Chase Cancer Center
   
Journal: Link
   
Date: 12/2004

Description:
Patients:
This phase II study involved 31 patients with low-grade non-Hodgkin's lymphoma. The median patient age was 62 years and 15 were male.

Treatment:
Patients were treated with the chemotherapy agent fludarabine and the immunotherapy agent interferon-alpha (IFN), which stimulates the immune system to attack cancer cells.

Toxicity:
The most severe adverse events were of grade 4 and included anemia, lymphopenia, and thrombocytopenia. Fever, fatigue, and nausea were also reported.

Results:
The median overall survival was 60.8 months.

Support:
This study was partially supported by the pharmaceutical company Roche.

Correspondence: Dr. Mitchell R. Smith; email: m_smith@fccc.edu

E-mail to a Friend Email Physician More Information